Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Takhzyro
Pharma
In competitive HAE market, CSL gains FDA approval for Andembry
With the FDA's approval of hereditary angioedema treatment Andembry, CSL is ready to take on Takeda’s blockbuster Takhzyro and BioCryst's Orladeyo.
Kevin Dunleavy
Jun 17, 2025 11:10am
Takeda expects patent expirations to weigh on earnings
May 12, 2023 11:10am
New HAE drugs from Takeda, BioCryst are gaining popularity
Mar 18, 2022 11:16am
Samsung, Moderna, Brii and more—Fierce Pharma Asia
Aug 27, 2021 9:20am
ICER is urging steep discounts on Takeda and CSL drugs
Aug 24, 2021 2:18pm
FDA delays Takeda's Eohilia as EMA extends dengue vaccine review
Jul 30, 2021 10:50am
